PROKIDNEY CORP (PROK)
KYG7S53R1049 - Common Stock
We assign a fundamental rating of 1 out of 10 to PROK. PROK was compared to 568 industry peers in the Biotechnology industry. PROK may be in some trouble as it scores bad on both profitability and health. PROK is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PROK had negative earnings in the past year.
PROK had a negative operating cash flow in the past year.
1.2 Ratios
The Return On Assets of PROK (-9.61%) is better than 87.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.61% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-55.38%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PROK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for PROK has been increased compared to 1 year ago.
Compared to 1 year ago, PROK has a worse debt to assets ratio.
2.2 Solvency
PROK has an Altman-Z score of -3.36. This is a bad value and indicates that PROK is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PROK (-3.36) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.36 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 17.09 indicates that PROK has no problem at all paying its short term obligations.
PROK's Current ratio of 17.09 is amongst the best of the industry. PROK outperforms 91.86% of its industry peers.
A Quick Ratio of 17.09 indicates that PROK has no problem at all paying its short term obligations.
The Quick ratio of PROK (17.09) is better than 91.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.09 | ||
| Quick Ratio | 17.09 |
3. Growth
3.1 Past
PROK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.78%.
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
PROK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.38% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.8%
EPS Next 2Y9.82%
EPS Next 3Y-10.84%
EPS Next 5Y7.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PROK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as PROK's earnings are expected to decrease with -10.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.82%
EPS Next 3Y-10.84%
5. Dividend
5.1 Amount
No dividends for PROK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROKIDNEY CORP
NASDAQ:PROK (12/20/2024, 8:00:00 PM)
After market: 1.6238 +0.11 (+7.54%)1.51
+0.05 (+3.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners37.07%
Inst Owner Change22.48%
Ins Owners3.3%
Ins Owner Change0.07%
Market Cap440.41M
Analysts80
Price Target4.76 (215.23%)
Short Float %11.45%
Short Ratio24.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.2%
Min EPS beat(2)5.99%
Max EPS beat(2)8.4%
EPS beat(4)4
Avg EPS beat(4)18.75%
Min EPS beat(4)5.99%
Max EPS beat(4)48.25%
EPS beat(8)7
Avg EPS beat(8)30.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-6.31%
EPS NQ rev (3m)8.14%
EPS NY rev (1m)-3.04%
EPS NY rev (3m)-13.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS-3.36
TBVpS-3.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.61% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-55.38%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 111.32% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.09 | ||
| Quick Ratio | 17.09 | ||
| Altman-Z | -3.36 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)403.51%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y-4.8%
EPS Next 2Y9.82%
EPS Next 3Y-10.84%
EPS Next 5Y7.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.44%
EBIT Next 3Y-9.83%
EBIT Next 5YN/A
FCF growth 1Y-74.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.63%
OCF growth 3YN/A
OCF growth 5YN/A